

Dominique Farge

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4330633/publications.pdf>

Version: 2024-02-01

103
papers

7,276
citations

81900

39
h-index

56724

83
g-index

130
all docs

130
docs citations

130
times ranked

6844
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparison of Low-Molecular-Weight Heparin and Warfarin for the Secondary Prevention of Venous Thromboembolism in Patients With Cancer. <i>Archives of Internal Medicine</i> , 2002, 162, 1729.	3.8	727
2	Autologous Hematopoietic Stem Cell Transplantation vs Intravenous Pulse Cyclophosphamide in Diffuse Cutaneous Systemic Sclerosis. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 2490.	7.4	566
3	International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 56-70.	3.8	469
4	2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. <i>Lancet Oncology</i> , The, 2019, 20, e566-e581.	10.7	458
5	Autologous hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 12 years' experience from the European Group for Blood and Marrow Transplantation Working Party on Autoimmune Diseases. <i>Haematologica</i> , 2010, 95, 284-292.	3.5	321
6	International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer. <i>Lancet Oncology</i> , The, 2016, 17, e452-e466.	10.7	315
7	Diagnosis and management of acute deep vein thrombosis: a joint consensus document from the European Society of Cardiology working groups of aorta and peripheral vascular diseases and pulmonary circulation and right ventricular function. <i>European Heart Journal</i> , 2018, 39, 4208-4218.	2.2	267
8	Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 2012, 47, 770-790.	2.4	256
9	Prevalence and factors associated with left ventricular dysfunction in the EULAR Scleroderma Trial and Research group (EUSTAR) database of patients with systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 218-221.	0.9	214
10	Autologous hematopoietic stem cell transplantation in multiple sclerosis. <i>Neurology</i> , 2015, 84, 981-988.	1.1	201
11	Long-term Outcomes After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis. <i>JAMA Neurology</i> , 2017, 74, 459.	9.0	199
12	Evolution, trends, outcomes, and economics of hematopoietic stem cell transplantation in severe autoimmune diseases. <i>Blood Advances</i> , 2017, 1, 2742-2755.	5.2	151
13	Long-term follow-up results after autologous haematopoietic stem cell transplantation for severe systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2008, 67, 98-104.	0.9	149
14	Secondary autoimmune diseases occurring after HSCT for an autoimmune disease: a retrospective study of the EBMT Autoimmune Disease Working Party. <i>Blood</i> , 2011, 118, 1693-1698.	1.4	140
15	Autologous Hematopoietic Stem Cell Transplantation for Refractory Crohn Disease. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 2524.	7.4	136
16	Cardiac involvement and treatment-related mortality after non-myeloablative haemopoietic stem-cell transplantation with unselected autologous peripheral blood for patients with systemic sclerosis: a retrospective analysis. <i>Lancet</i> , The, 2013, 381, 1116-1124.	18.7	129
17	Autologous haematopoietic stem cell transplantation and other cellular therapy in multiple sclerosis and immune-mediated neurological diseases: updated guidelines and recommendations from the EBMT Autoimmune Diseases Working Party (ADWP) and the Joint Accreditation Committee of EBMT and ISCT (IACIE). <i>Bone Marrow Transplantation</i> , 2020, 55, 283-306.	2.4	128
18	Skin involvement in scleroderma—where histological and clinical scores meet. <i>Rheumatology</i> , 2007, 46, 833-841.	1.9	123

#	ARTICLE	IF	CITATIONS
19	Autologous bone marrow transplantation in the treatment of refractory systemic sclerosis: early results from a French multicentre phase II study. <i>British Journal of Haematology</i> , 2002, 119, 726-739.	2.5	119
20	Clinical prediction of 5-year survival in systemic sclerosis: validation of a simple prognostic model in EUSTAR centres. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1788-1792.	0.9	107
21	Cardiopulmonary assessment of patients with systemic sclerosis for hematopoietic stem cell transplantation: recommendations from the European Society for Blood and Marrow Transplantation Autoimmune Diseases Working Party and collaborating partners. <i>Bone Marrow Transplantation</i> , 2017, 52, 1495-1503.	2.4	88
22	Autologous haematopoietic stem cell transplantation for systemic lupus erythematosus: data from the European Group for Blood and Marrow Transplantation registry. <i>Lupus</i> , 2013, 22, 245-253.	1.6	80
23	Allogeneic hematopoietic SCT for patients with autoimmune diseases. <i>Bone Marrow Transplantation</i> , 2009, 44, 27-33.	2.4	79
24	A Long-Term Follow-Up Study of Allogeneic Mesenchymal Stem/Stromal Cell Transplantation in Patients with Drug-Resistant Systemic Lupus Erythematosus. <i>Stem Cell Reports</i> , 2018, 10, 933-941.	4.8	79
25	Validation of French version of the Scleroderma Health Assessment Questionnaire (SSc HAQ). <i>Clinical Rheumatology</i> , 2005, 24, 3-10.	2.2	71
26	SCT for severe autoimmune diseases: consensus guidelines of the European Society for Blood and Marrow Transplantation for immune monitoring and biobanking. <i>Bone Marrow Transplantation</i> , 2015, 50, 173-180.	2.4	71
27	New autoimmune diseases after cord blood transplantation: a retrospective study of EUROCORD and the Autoimmune Disease Working Party of the European Group for Blood and Marrow Transplantation. <i>Blood</i> , 2013, 121, 1059-1064.	1.4	69
28	Update on mesenchymal stem cell-based therapy in lupus and scleroderma. <i>Arthritis Research and Therapy</i> , 2015, 17, 301.	3.5	67
29	Current state and future directions of autologous hematopoietic stem cell transplantation in systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 2071-2074.	0.9	58
30	Right heart thrombi in pulmonary embolism. <i>European Respiratory Journal</i> , 2016, 48, 1377-1385.	6.7	58
31	Autologous stem cell transplantation for progressive systemic sclerosis: a prospective non-interventional study from the European Society for Blood and Marrow Transplantation Autoimmune Disease Working Party. <i>Haematologica</i> , 2021, 106, 375-383.	3.5	57
32	Autologous hematopoietic stem cell transplantation in neuromyelitis optica: A registry study of the EBMT Autoimmune Diseases Working Party. <i>Multiple Sclerosis Journal</i> , 2015, 21, 189-197.	3.0	56
33	Long-term immune reconstitution and T cell repertoire analysis after autologous hematopoietic stem cell transplantation in systemic sclerosis patients. <i>Journal of Hematology and Oncology</i> , 2017, 10, 21.	17.0	51
34	Hematopoietic stem cell therapy for autoimmune diseases – Clinical experience and mechanisms. <i>Journal of Autoimmunity</i> , 2018, 92, 35-46.	6.5	51
35	Patterns and predictors of skin score change in early diffuse systemic sclerosis from the European Scleroderma Observational Study. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 563-570.	0.9	50
36	Allogeneic HSCT for Autoimmune Diseases: A Retrospective Study From the EBMT ADWP, IEWP, and PDWP Working Parties. <i>Frontiers in Immunology</i> , 2019, 10, 1570.	4.8	48

#	ARTICLE	IF	CITATIONS
37	Incidence of Venous Thromboembolism in Patients With Newly Diagnosed Pancreatic Cancer and Factors Associated With Outcomes. <i>Gastroenterology</i> , 2020, 158, 1346-1358.e4.	1.3	48
38	Association between D-Dimer levels and mortality in patients with coronavirus disease 2019 (COVID-19): a systematic review and pooled analysis. <i>JMV-Journal De Medecine Vasculaire</i> , 2020, 45, 268-274.	0.2	47
39	Compliance with recommendations of clinical practice in the management of venous thromboembolism in cancer: The CARMEN study. <i>Journal Des Maladies Vasculaires</i> , 2014, 39, 161-168.	0.6	46
40	Fatal Events in Cancer Patients Receiving Anticoagulant Therapy for Venous Thromboembolism. <i>Medicine (United States)</i> , 2015, 94, e1235.	1.0	43
41	Autologous Hematopoietic Stem Cell Transplant in Systemic Sclerosis: Quantitative High Resolution Computed Tomography of the Chest Scoring. <i>Journal of Rheumatology</i> , 2009, 36, 1460-1463.	2.0	38
42	Onset and outcome of pregnancy after autologous haematopoietic SCT (AH SCT) for autoimmune diseases: a retrospective study of the EBMT autoimmune diseases working party (ADWP). <i>Bone Marrow Transplantation</i> , 2015, 50, 216-220.	2.4	38
43	Resetting the immune response after autologous hematopoietic stem cell transplantation for autoimmune diseases. <i>Current Research in Translational Medicine</i> , 2016, 64, 107-113.	1.8	32
44	Haematopoietic stem cell transplantation in autoimmune diseases: From basic science to clinical practice. <i>Current Research in Translational Medicine</i> , 2016, 64, 71-82.	1.8	32
45	International and multidisciplinary expert recommendations for the use of biologics in systemic lupus erythematosus. <i>Autoimmunity Reviews</i> , 2017, 16, 650-657.	5.8	32
46	Incidence, risk factors, and outcomes of central venous catheter-related thromboembolism in breast cancer patients: the <sc>CAVECCAS</sc> study. <i>Cancer Medicine</i> , 2017, 6, 2732-2744.	2.8	30
47	Recent Advances in the Management of Cancer-Associated Thrombosis: New Hopes but New Challenges. <i>Cancers</i> , 2019, 11, 71.	3.7	30
48	Autologous Haematopoietic Stem Cell Transplantation for Crohn's Disease: A Retrospective Survey of Long-term Outcomes From the European Society for Blood and Marrow Transplantation. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 1097-1103.	1.3	29
49	Mesenchymal stromal cells for systemic sclerosis treatment. <i>Autoimmunity Reviews</i> , 2021, 20, 102755.	5.8	28
50	Hematopoietic stem cell transplantation for autoimmune diseases in the time of COVID-19: EBMT guidelines and recommendations. <i>Bone Marrow Transplantation</i> , 2021, 56, 1493-1508.	2.4	27
51	Therapy for Cancer-Related Thromboembolism. <i>Seminars in Oncology</i> , 2014, 41, 319-338.	2.2	26
52	Autologous HSCT is efficacious, but can we make it safer?. <i>Nature Reviews Rheumatology</i> , 2018, 14, 189-191.	8.0	26
53	General information for patients and carers considering haematopoietic stem cell transplantation (HSCT) for severe autoimmune diseases (ADs): A position statement from the EBMT Autoimmune Diseases Working Party (ADWP), the EBMT Nurses Group, the EBMT Patient, Family and Donor Committee and the Joint Accreditation Committee of ISCT and EBMT (JACIE). <i>Bone Marrow Transplantation</i> , 2019, 54, 933-942.	2.4	25
54	2019 international clinical practice guidelines for the treatment of venous thromboembolism – Authors' reply. <i>Lancet Oncology</i> , The, 2019, 20, e656.	10.7	25

#	ARTICLE	IF	CITATIONS
55	Transforming growth factor- β 2 increases interleukin-13 synthesis via GATA-3 transcription factor in T-lymphocytes from patients with systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2015, 17, 196.	3.5	22
56	Acute and fatal cardiotoxicity following high-dose cyclophosphamide in a patient undergoing autologous stem cell transplantation for systemic sclerosis despite satisfactory cardiopulmonary screening. <i>Bone Marrow Transplantation</i> , 2017, 52, 1674-1677.	2.4	22
57	Autoimmune cytopenias (AIC) following allogeneic haematopoietic stem cell transplant for acquired aplastic anaemia: a joint study of the Autoimmune Diseases and Severe Aplastic Anaemia Working Parties (ADWP/SAAWP) of the European Society for Blood and Marrow Transplantation (EBMT). <i>Bone Marrow Transplantation</i> , 2020, 55, 441-451.	2.4	22
58	Analysis of clinical factors affecting the rates of fatal pulmonary embolism and bleeding in cancer patients with venous thromboembolism. <i>Heliyon</i> , 2017, 3, e00229.	3.2	19
59	Left Ventricle Replacement Fibrosis Detected by CMR Associated With Cardiovascular Events in Systemic Sclerosis Patients. <i>Journal of the American College of Cardiology</i> , 2018, 71, 703-705.	2.8	19
60	Prognostic Factors for Clinical Response in Systemic Lupus Erythematosus Patients Treated by Allogeneic Mesenchymal Stem Cells. <i>Stem Cells International</i> , 2019, 2019, 1-7.	2.5	19
61	Clinical practice guidelines for prophylaxis of venous thromboembolism in cancer patients. <i>Thrombosis and Haemostasis</i> , 2016, 116, 618-625.	3.4	18
62	Reproducibility and Utility of the 6-minute Walk Test in Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2018, 45, 1273-1280.	2.0	17
63	LB0002â€¦The astis trial: Autologous stem cell transplantation versus IV pulse cyclophosphamide in poor prognosis systemic sclerosis, first results. <i>Annals of the Rheumatic Diseases</i> , 2013, 71, 151-151.	0.9	16
64	Lysyl oxidaseâ€”a possible role in systemic sclerosisâ€”associated pulmonary hypertension: a multicentre study. <i>Rheumatology</i> , 2019, 58, 1547-1555.	1.9	15
65	Adipose tissue-derived stromal vascular fraction for treating hands of patients with systemic sclerosis: a multicentre randomized trial Autologous AD-SVF versus placebo in systemic sclerosis. <i>Rheumatology</i> , 2022, 61, 1936-1947.	1.9	15
66	New autoimmune diseases after autologous hematopoietic stem cell transplantation for multiple sclerosis. <i>Bone Marrow Transplantation</i> , 2021, 56, 1509-1517.	2.4	14
67	Quality of life in cancer patients undergoing anticoagulant treatment with LMWH for venous thromboembolism: the QUAVITEC study on behalf of the Groupe Francophone Thrombose et Cancer (GFTC). <i>Oncotarget</i> , 2018, 9, 26990-26999.	1.8	13
68	Autologous haematopoietic stem cell transplantation (HSCT) for anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis: a retrospective survey of patients reported to European Society for Blood and Marrow Transplantation (EBMT) registry. <i>Bone Marrow Transplantation</i> , 2020, 55, 1512-1515.	2.4	12
69	Women, thrombosis, and cancer: A gender-specific analysis. <i>Thrombosis Research</i> , 2017, 151, S21-S29.	1.7	11
70	Recent advances in the treatment and prevention of venous thromboembolism in cancer patients: role of the direct oral anticoagulants and their unique challenges. <i>F1000Research</i> , 2019, 8, 974.	1.6	11
71	Simultaneous progressive multifocal leukoencephalopathy, Epstein-Barr virus (EBV) latent infection and cerebral parenchymal infiltration during chronic lymphocytic leukemia. <i>Leukemia</i> , 1994, 8, 318-21.	7.2	11
72	Association of Autologous Hematopoietic Stem Cell Transplantation in Systemic Sclerosis With Marked Improvement in Healthâ€”Related Quality of Life. <i>Arthritis and Rheumatology</i> , 2021, 73, 305-314.	5.6	10

#	ARTICLE	IF	CITATIONS
73	Autologous stem cell transplantation in scleroderma. <i>Presse Medicale</i> , 2021, 50, 104065.	1.9	10
74	Evaluating the clinical effectiveness of autologous haematopoietic stem cell transplantation versus disease-modifying therapy in multiple sclerosis using a matching-adjusted indirect comparison: an exploratory study from the Autoimmune Diseases Working Party (ADWP) of the European Society of Bone and Marrow Transplantation (EBMT). <i>Bone Marrow Transplantation</i> , 2020, 55, 1473-1475.	2.4	9
75	How to screen and diagnose deep venous thrombosis (DVT) in patients hospitalized for or suspected of COVID-19 infection, outside the intensive care units. <i>JMV-Journal De Medecine Vasculaire</i> , 2020, 45, 334-343.	0.2	8
76	Drug-drug interaction (DDI) with direct oral anticoagulant (DOAC) in patients with cancer. <i>JMV-Journal De Medecine Vasculaire</i> , 2020, 45, 6S31-6S38.	0.2	8
77	Hematopoietic stem cell transplantation in chronic inflammatory demyelinating polyneuropathy: French experience about four patients, under the behalf of French society for bone marrow transplantation. <i>Journal of Neurology</i> , 2021, 268, 1536-1539.	3.6	8
78	Implementing Thrombosis Guidelines in Cancer Patients: A Review. <i>Rambam Maimonides Medical Journal</i> , 2014, 5, e0041.	1.0	8
79	Prophylaxis of venous thromboembolism in cancer patients. <i>Expert Review of Hematology</i> , 2016, 9, 535-539.	2.2	7
80	Women, thrombosis, and cancer. <i>Thrombosis Research</i> , 2019, 181, S47-S53.	1.7	7
81	Autologous haematopoietic stem cell transplantation (AHSCT) in autoimmune disease adult patients in France: analysis of the long-term outcome from the French Society for Bone Marrow Transplantation and Cellular Therapy (SFGM-TC). <i>Clinical Rheumatology</i> , 2019, 38, 1501-1511.	2.2	7
82	Long term outcomes of the French ASTIS systemic sclerosis cohort using the global rank composite score. <i>Bone Marrow Transplantation</i> , 2021, 56, 2259-2267.	2.4	7
83	Autologous HSCT in systemic sclerosis: a step forward. <i>Lancet, The</i> , 2011, 378, 460-462.	13.7	6
84	Different Types of Statins and All-Cause Mortality during Anticoagulation for Venous Thromboembolism: Validation Study from RIETE Registry. <i>TH Open</i> , 2020, 04, e236-e244.	1.4	6
85	Quantification of Antifibrillar (anti-U3 RNP) Antibodies: A New Insight for Patients with Systemic Sclerosis. <i>Diagnostics</i> , 2021, 11, 1064.	2.6	6
86	Clinical Course of Venous Thromboembolism in Patients with Pancreatic Cancer: Insights from the RIETE Registry. <i>Thrombosis and Haemostasis</i> , 2018, 118, 1119-1122.	3.4	4
87	Effectiveness of a multidisciplinary care program for the management of venous thromboembolism in cancer patients: a pilot study. <i>Journal of Thrombosis and Thrombolysis</i> , 2022, 53, 417-424.	2.1	4
88	Changes on chest HRCT in systemic sclerosis-related interstitial lung disease after autologous haematopoietic stem cell transplantation. <i>Rheumatology</i> , 2023, 62, SI32-SI42.	1.9	4
89	Cardiac Assessment Before Stem Cell Transplantation for Systemic Sclerosisâ€”Reply. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 1803.	7.4	3
90	Management of cancer-related thrombosis in the era of direct oral anticoagulants: A comprehensive review of the 2019 ITAC-CME clinical practice guidelines. On behalf of the Groupe Francophone Thrombose et Cancer (GFTC). <i>JMV-Journal De Medecine Vasculaire</i> , 2020, 45, 28-40.	0.2	3

#	ARTICLE	IF	CITATIONS
91	Autologous Hematopoietic Stem Cell Transplantation (HSCT) for Autoimmune Diseases: 10 Years Experience from the European Group for Blood and Marrow Transplantation (EBMT) Working Party on Autoimmune Diseases. <i>Blood</i> , 2008, 112, 164-164.	1.4	3
92	Gender differences in early systemic sclerosis patients: a report from the EULAR scleroderma trials and research group (EUSTAR) database. <i>Clinical and Experimental Rheumatology</i> , 2018, 36 Suppl 113, 68-75.	0.8	3
93	Haematopoietic stem cell transplantation for severe autoimmune diseases in children: A review of current literature, registry activity and future directions on behalf of the autoimmune diseases and paediatric diseases working parties of the European Society for Blood and Marrow Transplantation. <i>British Journal of Haematology</i> , 2022, 198, 24-45.	2.5	3
94	Patient education program at the forefront of cancer-associated thrombosis care. <i>JMV-Journal De Medecine Vasculaire</i> , 2021, 46, 215-223.	0.2	2
95	PTU-083 Substantial histological improvement following haemopoetic stem cell transplantation: Abstract PTU-083 Table 1. <i>Gut</i> , 2015, 64, A97.1-A97.	12.1	1
96	How to treat venous thromboembolism (TVE) in cancer patients: ten years of multidisciplinary team meetings (MDTM) at Saint-Louis Hospital. <i>JMV-Journal De Medecine Vasculaire</i> , 2020, 45, 6S24-6S30.	0.2	1
97	Clinical determinants of elevated systolic pulmonary artery pressure measured by transthoracic Doppler echocardiography in early systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2017, 35 Suppl 106, 114-121.	0.8	1
98	FRI0244 Lysyl Oxidase as A Biomarker in Systemic Sclerosis A Multicenter Study. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 522.1-522.	0.9	0
99	What is the current state of thrombosis treatment and prevention in cancer patients?. <i>JMV-Journal De Medecine Vasculaire</i> , 2020, 45, 6S1-6S2.	0.2	0
100	Incidence and Risk Factors for Secondary Autoimmune Diseases (AD) After Hematopoietic Stem Cell Transplantation (HSCT) for a Severe Autoimmune Disease-A Retrospective EBMT WP AD Study. <i>Blood</i> , 2010, 116, 2322-2322.	1.4	0
101	International guidelines for antithrombotics in cancer patients.. <i>Journal of Clinical Oncology</i> , 2012, 30, e13062-e13062.	1.6	0
102	Does Ex Vivo CD34+ Cell Selection Change the Outcome of Systemic Sclerosis Patients Treated with Autologous Hematopoietic Stem Cell Transplantation (AHSCT), an Adwp EBMT Study?. <i>Blood</i> , 2014, 124, 2517-2517.	1.4	0
103	Improving Treatment Related Mortality over Time - Data from the Non-Observational Trial on Autologous Stem Cell Transplantation in Systemic Sclerosis By the EBMT Autoimmune Diseases Working Party (ADWP). <i>Blood</i> , 2018, 132, 3431-3431.	1.4	0